Zydus Lifesciences Limited (ZYDUSLIFE) Price & Analysis

Compare

8 Followers

ZYDUSLIFE Stock Chart & Stats

₹921.80

-₹19.40(-1.94%)

At close: Jan 08 4:00 PM EST

₹921.80

-₹19.40(-1.94%)

Day’s Range― - ―

52-Week Range₹797.05 - ₹1,059.00

Previous CloseN/A

Volume1.39M

Average Volume (3M)33.86K

Market Cap

₹912.50B

Enterprise Value₹981.09B

Total Cash (Recent Filing)₹56.37B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)18.8

Beta0.61

Next Earnings

May 15, 2026

EPS Estimate

7.62

Next Dividend Ex-DateN/A

Dividend Yield1.19%

Share Statistics

EPS (TTM)10.03

Shares Outstanding1,006,234,000

10 Day Avg. Volume33,597

30 Day Avg. Volume33,862

Financial Highlights & Ratios

PEG Ratio1.05

Price to Book (P/B)3.69

Price to Sales (P/S)3.80

P/FCF Ratio17.44

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹1,015.00

Price Target Upside10.11% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)45.3

Revenue Forecast (FY)₹263.80B

Bulls Say, Bears Say

Bulls Say

Revenue GrowthStrong revenue growth indicates expanding market presence and product demand, supporting long-term business sustainability and profitability.

Cash Flow GenerationRobust cash flow generation enhances financial flexibility, enabling strategic investments and debt management, which supports long-term growth.

Balance Sheet HealthA low debt-to-equity ratio indicates financial stability, reducing risk and providing a solid foundation for sustainable growth and operational resilience.

Bears Say

High Total LiabilitiesHigh total liabilities may strain financial resources and limit flexibility, potentially impacting the company's ability to invest in growth opportunities.

Potential Risk From LiabilitiesWhile mitigated by strong equity, high liabilities can still pose risks to financial health, affecting the company's ability to withstand economic downturns.

No Recent Corporate EventsLack of recent corporate events or strategic initiatives may indicate missed opportunities for growth or innovation, potentially impacting long-term competitiveness.

Zydus Lifesciences Limited News

Zydus Lifesciences Publishes Q3 and 9M FY26 Investor Presentation

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) has shared an update. Zydus Lifesciences Limited has released an investor presentation...

23d ago

Zydus Lifesciences Posts Strong Q3 and 9M FY26 Growth With Higher Margins

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) has issued an update. Zydus Lifesciences Limited reported a strong operational performance...

23d ago

Zydus Unveils World’s First Nivolumab Biosimilar in India to Broaden Cancer Care Access

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) has provided an update. Zydus Lifesciences has launched Tishtha, the world’s first...

1M ago

Zydus Lifesciences Opens Special Six-Month Window for Re-Lodgement of Physical Share Transfers

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) has shared an update. Zydus Lifesciences Limited has announced, via newspaper publication,...

2M ago

Zydus Lifesciences Ties Up With Myriad Genetics to Bring Advanced Cancer-Risk Tests to India

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) has issued an announcement. Zydus Lifesciences has signed an exclusive agreement with...

3M ago

Zydus Lifesciences Secures Shareholder Approval for Fundraising Initiative

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) just unveiled an announcement. Zydus Lifesciences Limited announced the successful passage of...

3M ago

Zydus Lifesciences Issues Notice on Lost Share Certificate

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) just unveiled an announcement. Zydus Lifesciences Limited has announced the loss of...

4M ago

Zydus Lifesciences Releases Unaudited Financial Results for Q2 2025

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) has issued an update. Zydus Lifesciences Limited announced the publication of its...

4M ago

Zydus Lifesciences Completes Full Acquisition of Amplitude Surgical

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) has provided an announcement. Zydus Lifesciences Limited has completed the acquisition of...

4M ago

Zydus Lifesciences Gains Health Canada Approval for Mesalamine Suppositories

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) has shared an update. Zydus Lifesciences Limited has received approval from Health...

4M ago

ZYDUSLIFE FAQ

What was Zydus Lifesciences Limited’s price range in the past 12 months?

Zydus Lifesciences Limited lowest stock price was ₹797.05 and its highest was ₹1059.00 in the past 12 months.

What is Zydus Lifesciences Limited’s market cap?

Zydus Lifesciences Limited’s market cap is ₹912.50B.

When is Zydus Lifesciences Limited’s upcoming earnings report date?

Zydus Lifesciences Limited’s upcoming earnings report date is May 15, 2026 which is in 72 days.

How were Zydus Lifesciences Limited’s earnings last quarter?

Zydus Lifesciences Limited released its earnings results on Feb 09, 2026. The company reported ₹10.03 earnings per share for the quarter, missing the consensus estimate of ₹10.832 by -₹0.802.

Is Zydus Lifesciences Limited overvalued?

According to Wall Street analysts Zydus Lifesciences Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zydus Lifesciences Limited pay dividends?

Zydus Lifesciences Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 1.19%. See more information on Zydus Lifesciences Limited dividends here

What is Zydus Lifesciences Limited’s EPS estimate?

Zydus Lifesciences Limited’s EPS estimate is 7.62.

How many shares outstanding does Zydus Lifesciences Limited have?

Zydus Lifesciences Limited has 1,006,234,000 shares outstanding.

What happened to Zydus Lifesciences Limited’s price movement after its last earnings report?

Zydus Lifesciences Limited reported an EPS of ₹10.03 in its last earnings report, missing expectations of ₹10.832. Following the earnings report the stock price went up 3.97%.

Which hedge fund is a major shareholder of Zydus Lifesciences Limited?

Currently, no hedge funds are holding shares in IN:ZYDUSLIFE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Zydus Lifesciences Limited

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

Zydus Lifesciences Limited (ZYDUSLIFE) Earnings & Revenues

Historic Earnings Reports

ZYDUSLIFE Stock 12 Month Forecast

Average Price Target

₹1,015.00

▲(10.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"865":"₹865","916":"₹916","967":"₹967","1018":"₹1,018","1069":"₹1,069"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1020,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.02K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1015,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.01K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1010,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.01K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[865,916,967,1018,1069],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,879.25,890.0769230769231,900.9038461538462,911.7307692307693,922.5576923076923,933.3846153846154,944.2115384615385,955.0384615384615,965.8653846153846,976.6923076923077,987.5192307692307,998.3461538461538,1009.1730769230769,{"y":1020,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,879.25,889.6923076923077,900.1346153846154,910.5769230769231,921.0192307692307,931.4615384615385,941.9038461538462,952.3461538461538,962.7884615384615,973.2307692307693,983.6730769230769,994.1153846153846,1004.5576923076923,{"y":1015,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,879.25,889.3076923076923,899.3653846153846,909.4230769230769,919.4807692307693,929.5384615384615,939.5961538461538,949.6538461538462,959.7115384615385,969.7692307692307,979.8269230769231,989.8846153846154,999.9423076923077,{"y":1010,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1068.36,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":990.5,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":963.61,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":962.62,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":962.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":959.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":866.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":877.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":990.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":948.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":991.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":914.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":879.25,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >